RMB. I don't see it as a sell the news event . Hopefully there will be some discussion on their DME drug RZ402 and if they have received any BP interest. Some times the Ceo can say something like " We've received interest " etc without legally having to file an SEC required PR. Or " yes we are in talks but can't comment any further " or a watered down version of such
RMB. Well so far this has been the stock of the year for me . Buying in Feb , then selling 50% once it doubled to recover my initial investment ...now just letting the rest ride to see where this Co takes us. Any 20% drop will make me reconsider my sizing ...portfolio risk mgt.
Before the DME data this Co had a market cap close to $100m . The DME data alone would now seem to justify a BP paying at least that just for RZ402 . JMO Kiwi